CNTN6

Across TCGA pan-cancer cohorts, CNTN6 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated CNTN6 data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CNTN6 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CNTN6 expression acts as an unfavorable survival marker, although some lineages such as LUSC and UCEC show a favorable association.

LUSC, UCEC, and SCLC are the cancer types where CNTN6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.678	0.373	.002	22	view →
UCEC	DFS	Median	All	0.796	0.626	.012	22	view →
SCLC	OS	Median	II,III,IV	0.274	0.707	.006	12	view →
BLCA	DFS	Median	IV	0.110	0.479	.005	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	9	view →
LIHC	DFS	Median	All	0.221	0.558	.016	6	view →
SKCM	DFS	Median	All	0.072	0.243	.009	5	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

CNTN6–LUSC (DFS)

Open the LUSC breakdown →